Hypothesis: VPAC G protein-coupled receptors for vasoactive intestinal peptide constitute a dynamic system for signaling T cells from plasma membrane and nuclear membrane complexes
- PMID: 16934888
- DOI: 10.1016/j.regpep.2006.04.022
Hypothesis: VPAC G protein-coupled receptors for vasoactive intestinal peptide constitute a dynamic system for signaling T cells from plasma membrane and nuclear membrane complexes
Abstract
The vasoactive intestinal peptide (VIP)-VPAC(1) and VPAC(2) G protein-coupled receptor (GPCR) systems are autocrine and paracrine regulators of diverse T cell functions. It has been recognized that VIP evokes two types of T cell responses. The first are rapid in onset and brief in duration, such as altered traffic in blood, lymphoid corridors, and tissues. The second are slow in onset and sustained in duration, such as enhanced helper T cell (Th) differentiation in the thymus and increased survival in lymphoid tissues with biases favoring the Th2-type effector and memory subsets. Investigations of some other sets of GPCRs for peptide and lipid mediators have demonstrated expression both in nuclear membranes and plasma membranes with respective linkages to responses that are slow in onset and sustained, and those that are rapid in onset and brief in duration. The hypothesis presented in this paper suggests that plasma membrane VPAC receptors transduce short-term effects of exogenous VIP on T cell effector functions, whereas nuclear VPAC receptors mediate endogenous VIP alterations in differentiation, proliferation, and survival. The types of substantial additional proof needed to support this hypothesis are described, as are its advantages for more selective VIP-directed therapies.
Similar articles
-
Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer.Peptides. 2010 Nov;31(11):2035-45. doi: 10.1016/j.peptides.2010.07.024. Epub 2010 Aug 5. Peptides. 2010. PMID: 20691743
-
Vasoactive intestinal peptide-mediated Th17 differentiation: an expanding spectrum of vasoactive intestinal peptide effects in immunity and autoimmunity.Ann N Y Acad Sci. 2008 Nov;1144:83-9. doi: 10.1196/annals.1418.020. Ann N Y Acad Sci. 2008. PMID: 19076367 Review.
-
Pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors: distribution and involvement in the secretion of Podarcis sicula adrenal gland.J Endocrinol. 2008 Feb;196(2):291-303. doi: 10.1677/JOE-07-0127. J Endocrinol. 2008. PMID: 18252952
-
Endogenous ligands of PACAP/VIP receptors in the autocrine-paracrine regulation of the adrenal gland.Int Rev Cytol. 2006;249:1-51. doi: 10.1016/S0074-7696(06)49001-X. Int Rev Cytol. 2006. PMID: 16697281 Review.
-
VPAC and PAC receptors: From ligands to function.Pharmacol Ther. 2009 Mar;121(3):294-316. doi: 10.1016/j.pharmthera.2008.11.006. Epub 2008 Dec 6. Pharmacol Ther. 2009. PMID: 19109992 Review.
Cited by
-
Activation of Th lymphocytes alters pattern expression and cellular location of VIP receptors in healthy donors and early arthritis patients.Sci Rep. 2019 May 14;9(1):7383. doi: 10.1038/s41598-019-43717-2. Sci Rep. 2019. PMID: 31089161 Free PMC article.
-
Human CD4+CD45RA+ T Cells Behavior after In Vitro Activation: Modulatory Role of Vasoactive Intestinal Peptide.Int J Mol Sci. 2022 Feb 20;23(4):2346. doi: 10.3390/ijms23042346. Int J Mol Sci. 2022. PMID: 35216459 Free PMC article.
-
An Overview of VPAC Receptors in Rheumatoid Arthritis: Biological Role and Clinical Significance.Front Endocrinol (Lausanne). 2019 Oct 22;10:729. doi: 10.3389/fendo.2019.00729. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 31695683 Free PMC article. Review.
-
Perspective is everything: an irreverent discussion of CNS-immune system interactions as viewed from different scientific traditions.Brain Behav Immun. 2007 May;21(4):367-73. doi: 10.1016/j.bbi.2006.11.012. Epub 2007 Jan 17. Brain Behav Immun. 2007. PMID: 17234380 Free PMC article. Review.
-
Modular transcriptional repertoire and MicroRNA target analyses characterize genomic dysregulation in the thymus of Down syndrome infants.Oncotarget. 2016 Feb 16;7(7):7497-533. doi: 10.18632/oncotarget.7120. Oncotarget. 2016. PMID: 26848775 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources